Search results
-
Low-Dose Naltrexone restored TRPM3 ion channel function in Natural Killer cells from long COVID patients, 2025, Martini et al
I have a bit of a trouble interpreting this value. With a frequentist approach, the p-value measures the probability of obtaining the observed results assuming that the null hypothesis is true. So if the null hypothesis is "there is no difference between LDN LC and HC", the probability of...- Kronos
- Post #15
- Forum: Long Covid research
-
USA: The RECOVER Initiative - Long Covid research
Ar en't the results of the RESILIENT study quite significant though, or do you consider that poor efficiency [no offense, genuine question]? https://www.healthrising.org/blog/2024/04/15/tonix-tomnya-fibromyalgia-sleep-pain/ Meanwhile, they are going ahead with FDA approval...- Kronos
- Post #324
- Forum: Long Covid news
-
Trial Report Antibody-mediated autoimmunity in symptom-based disorders: position statement and proceedings from an international workshop, 2024, Mountford et al
Just wanted to add: The company behind the trial (UCB) has released some limited results: "The phase 2a study with rozanolixizumab in severe fibromyalgia syndrome showed statistically significant superiority to placebo but did not meet predefined criteria for progression. [...] UCB decided not...- Kronos
- Post #3
- Forum: ME/CFS research